This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic Receives FDA's Go Ahead for EFS Study on TTVR
by Zacks Equity Research
Medtronic (MDT) begins the FDA-approved EFS of Intrepid TTVR system following the receipt of the Breakthrough Device Designation from the regulatory authority.
Here's Why You Should Hold on to Medtronic Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on robust segmental growth and strong ventilators sales.
3 Remote Patient Monitoring Stocks in Focus Amid Coronavirus
by Sriparna Ghosal
In the wake of the pandemic, the remote patient monitoring space continues to thrive on a number of positive developments.
The Zacks Analyst Blog Highlights: Medtronic, Abbott Laboratories, Myriad Genetics, Zimmer Biomet and General Electric
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, Abbott Laboratories, Myriad Genetics, Zimmer Biomet and General Electric
3 Coronavirus-Led Threats to MedTech That May Linger
by Urmimala Biswas
Let us delve deeper to get an insight into the not-so-talked-about but intense threats to MedTech.
Medtronic (MDT) Plans Up to $475M of Annual Cost Savings
by Zacks Equity Research
Medtronic (MDT) expects its new operating model to help it become more focused in terms of speeding up research and developments.
Medtronic's Pediatric Diabetes Device Gets Regulatory Nod
by Zacks Equity Research
MiniMed 770G is Medtronic's (MDT) MiniMed 670G System's upgraded version.
Medtronic's (MDT) Cryoablation Suited for Patients With PAF
by Zacks Equity Research
Medtronic's (MDT) cryoablation therapy's superiority for the treatment of PAF over currently available AAD treatment gets reflected in trial results.
Medtronic (MDT) Sees Trend Rebound Amid Coronavirus Crisis
by Zacks Equity Research
Medtronic's (MDT) procedure volumes start to recover in multiple markets globally.
The Zacks Analyst Blog Highlights: Microsoft, Oracle, Medtronic, Booking and Cigna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Oracle, Medtronic, Booking and Cigna
Tandem Diabetes' Advanced Insulin Pump Study Results Favorable
by Zacks Equity Research
Per the DCLP5 study, Tandem Diabetes' (TNDM) insulin pump with Control-IQ technology suitable for use in children aged six to 13 years, which has been published in the NEJM.
Top Research Reports for Microsoft, Oracle & Medtronic
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Oracle (ORCL) and Medtronic (MDT).
Company News for Aug 26, 2020
by Zacks Equity Research
Companies in the news are: MDT, SJM, AAL, IMVT
Stock Futures Mostly Higher on Trade Talks, Dow's Shake-Up in Focus
by Zacks Equity Research
This morning, Treasury Secretary Steven Mnuchin and Trade Representative Robert Lighthizer had a telephonic discussion with Chinese vice premier Liu He.
Medtronic's (MDT) Q1 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
Barring Respiratory, Gastrointestinal & Renal, Medtronic (MDT) registers dismal performance in all business segments and geographies in Q1.
Strong Market Momentum Continues
by Zacks Equity Research
Strong Market Momentum Continues
Medtronic (MDT) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 195.24% and 21.06%, respectively, for the quarter ended July 2020. Do the numbers hold clues to what lies ahead for the stock?
Medtronic's (MDT) Evolut TAVR Label Expansion Gets FDA Nod
by Zacks Equity Research
Medtronic's (MDT) Low Risk Bicuspid Study shows bicuspid patients implanted with Evolut TAVR had low rates (1.3%) of all-cause mortality.
Medtronic Initiates Post-Market ELITE Study for SNM Therapy
by Zacks Equity Research
Medtronic's (MDT) ELITE study is expected to reinforce long-term safety, efficacy and patient benefit from the SNM therapy.
Medtronic Publishes IN.PACT AV Access Trial Study Results
by Zacks Equity Research
Medtronic's (MDT) IN.PACT AV demonstrates significant reductions in hospital visits for AV fistulae maintenance, which is leading to successful and uninterrupted dialysis of ESRD patients.
Will Medtronic's (MDT) Emergent Procedures Drive Q1 Earnings?
by Zacks Equity Research
Medtronic's (MDT) cardiac rhythm business might have recorded growth given several ICD launches in Q1.
Earnings Preview: Medtronic (MDT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medtronic (MDT) Plans $160 Million R&D Investment in India
by Zacks Equity Research
The newest expansion plan of MEIC will help Medtronic (MDT) advance in the field of pain alleviation and restoration of health.
Medtronic Plans New Acquisition in AI-Driven Diabetes Care
by Zacks Equity Research
Medtronic's (MDT) acquisition of Companion Medical aims to expand service to diabetics using multiple daily injections for diabetes management.
New Strong Sell Stocks for August 4th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today